# Aipore

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aipore

- Industry: Medical Devices & Equipment
- Headquarters: Tokyo, Japan
- Website: www.aipore.com
- Total disclosed funding: $3.7M
- Latest round: Series B (Jul 31, 2023)
- Investors on record: 2

## About

Aipore Inc., based in Japan, specializes in advanced particle measurement technology using AI to detect viruses, bacteria, and exosomes with high precision.Founded in 2018 in Tokyo, Japan, Aipore Inc. is dedicated to developing cutting-edge measurement solutions. The company has completed 3 deals, with the latest being a Series B funding round in July 2023, raising JPY 200 million from Osaka University Venture Capital. Aipore does not have any known subsidiaries or parent companies.Aipore focuses on advanced particle measurement technology, specifically targeting viruses, bacteria, and exosomes through its innovative AI-driven solutions. Their core product offerings include a highly precise pore sensor module and a microparticle measurement device that leverage semiconductor microfabrication to achieve superior measurement stability and accuracy beyond conventional nanopore methods. These technologies enable real-time identification of various viral strains and bacterial subtypes, along with determining viability and estimating the origins of exosomes. Released in 2020, their research and development solutions cater to a diverse clientele across multiple sectors including healthcare, diagnostics, and environmental monitoring. The products are marketed primarily in regions such as North America, Europe, and Asia, where there is a growing demand for rapid and accurate bio-detection and analysis.Aipore generates revenue through various direct sales channels, including partnerships and collaborations with research institutions, diagnostics companies, and other enterprises requiring advanced particle measurement capabilities. The transactional structure often involves direct sales of their flagship products, such as their pore sensor module and associated AI identification systems, to B2B clients, which may include laboratories and healthcare providers. Clients typically engage in one-time purchases or may explore ongoing partnerships for technology integration and support. The revenue model is further enhanced by potential subscription-based services for software updates and technical support, ensuring continual engagement with their client base. This structured approach allows for the establishment of long-term relationships, vital for continuous innovation and customer satisfaction in the rapidly evolving field of particle measurement technology.In July 2023, Aipore Inc. raised JPY 200 million in Series B funding from Osaka University Venture Capital. The investment will be utilized to accelerate the development of testing products for point-of-care testing (POCT) and to increase the variation of testing products. Aipore's strategy includes plans to expand its market presence by targeting new regions and sectors, although specific markets for future expansion have not been disclosed.

## Funding rounds

- Series B, Jul 31, 2023, $1.4M — Osaka University Venture Capital
- Series A, Oct 26, 2020, $2.3M — SMBC Venture Capital, Osaka University Venture Capital

## Investors

- SMBC Venture Capital (https://capitalatlas.ai/funds/smbc-venture-capital) — Series A
- Osaka University Venture Capital (https://capitalatlas.ai/funds/osaka-university-venture-capital) — Series A, Series B